AVEXIS RECEIVES FDA APPROVAL FOR ZOLGENSMA®, THE FIRST AND ONLY GENE THERAPY FOR PEDIATRIC PATIENTS WITH SPINAL MUSCULAR ATROPHY (SMA)
確定! 回上一頁